A Study of Donanemab (LY3002813) in Healthy Chinese Participants

NCT05533411 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Donanemab
DRUG: Placebo

Sponsor

Eli Lilly and Company